Organogenesis (ORGO) Set to Announce Quarterly Earnings on Friday

Share on StockTwits

Organogenesis (NASDAQ:ORGO) is scheduled to release its earnings data before the market opens on Friday, May 10th. Analysts expect Organogenesis to post earnings of ($0.10) per share for the quarter.

Organogenesis stock opened at $7.00 on Thursday. Organogenesis has a one year low of $6.28 and a one year high of $310.90.

Several research firms have commented on ORGO. BTIG Research began coverage on shares of Organogenesis in a research report on Friday, April 12th. They set a “buy” rating and a $12.00 target price on the stock. Credit Suisse Group began coverage on shares of Organogenesis in a research report on Thursday, May 2nd. They set an “outperform” rating and a $9.00 target price on the stock. CIBC began coverage on shares of Organogenesis in a research report on Wednesday, April 17th. They set an “outperform” rating and a $11.00 target price on the stock. Oppenheimer began coverage on shares of Organogenesis in a research report on Wednesday, April 17th. They set an “outperform” rating and a $11.00 target price on the stock. Finally, SunTrust Banks began coverage on shares of Organogenesis in a research report on Thursday, April 11th. They set a “buy” rating and a $11.00 target price on the stock. Five research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus price target of $10.80.

TRADEMARK VIOLATION WARNING: This report was originally reported by Equities Focus and is the sole property of of Equities Focus. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.equitiesfocus.com/2019/05/09/organogenesis-orgo-set-to-announce-quarterly-earnings-on-friday.html.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types.

Further Reading: Beige Book

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.